ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting, held on Jan 24, 2026 in Orlando, Florida. Details and highlights may be found below. Addition of Two New Directors Allesandro PudduAlessandro Puddu is an Italian Chartered Accountant and Statutory Auditor with over 10 years of experience in audit, corporate advisory and financial reporting for ...

Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition The expected closing date for the transaction is Dec 31, 2025. ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that it has signed an agreem ...

Core Points - Nutriband Inc. has declared a 25% preferred stock dividend, with shareholders of record on July 25, 2025, receiving one preferred share for every four common shares held, payable on August 5, 2025 [1] - Each preferred share will be convertible to one common share following FDA approval of the AVERSA Fentanyl product, and if unconverted, will receive annual cash dividends from company profits as determined by the Board of Directors [2] - The CEO emphasized the company's focus on creating shareholder value and advancing the commercialization of the AVERSA Fentanyl product, highlighting recent progress in manufacturing scale-up with Kindeva [3] Product Information - AVERSA™ technology is designed to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, particularly fentanyl, while ensuring accessibility for patients in need [4] - Nutriband is primarily focused on developing transdermal pharmaceutical products, with the AVERSA™ abuse-deterrent fentanyl patch as its lead product [5] Company Overview - Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products, with a strong emphasis on abuse-deterrent technologies [5]